Current Opinion in Pharmacology最新文献_第2页

Guiding contributions to Current Opinion in Pharmacology 对药理学当前观点的指导性贡献。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2026-01-14 DOI: 10.1016/j.coph.2026.102610

Sheng-Tao Hou

引用次数: 0

Real-world evidence supporting orphan drugs approvals for rare neuromuscular disorders in the European Union and the United States: Review of public assessment reports (2015–2025) 支持欧盟和美国罕见神经肌肉疾病孤儿药批准的真实证据：公共评估报告回顾（2015-2025）

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-14 DOI: 10.1016/j.coph.2025.102586

Beliu García-Parra , Josep M. Guiu , Mónica Povedano , Pilar Modamio

{"title":"Real-world evidence supporting orphan drugs approvals for rare neuromuscular disorders in the European Union and the United States: Review of public assessment reports (2015–2025)","authors":"Beliu García-Parra , Josep M. Guiu , Mónica Povedano , Pilar Modamio","doi":"10.1016/j.coph.2025.102586","DOIUrl":"10.1016/j.coph.2025.102586","url":null,"abstract":"<div><div>Real-world data (RWD) and real-world evidence (RWE) are becoming essential complements to conventional clinical trials for drug assessment, particularly for rare neuromuscular disorders where small patient populations heighten outcome uncertainty. Robust RWE could reduce that uncertainty and inform regulatory decisions on orphan drugs (ODs). To review how the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have incorporated RWE into OD approvals for neuromuscular diseases from January 2015 to January 2025. We reviewed all publicly available EMA European Public Assessment Reports and FDA review packages for ODs targeting neuromuscular indications. Each document was screened for mention of RWD sources and by the regulatory weight assigned to the resulting RWE. We identified 14 OD approvals by the EMA and 13 by the FDA, with greater use of RWE by the FDA. Indications comprised spinal muscular atrophy (3/3 EMA/FDA), amyotrophic lateral sclerosis (1/3), amyloid neuropathies (2/2), Friedreich ataxia (1/1), Lambert–Eaton syndrome (1/1), myasthenia gravis (2/2), myotonic disorders (1/0), and Duchenne muscular dystrophy (2/1). Among 18 evaluable dossiers, clinical outcome assessments (COA) were reported as follows: patient-reported outcomes - 39.1%, clinician-reported outcomes - 34.7%, observer-reported outcomes - 13.1 %, and performance outcomes - 13.1%. Only tofersen incorporated all COA types. The use of RWE for the evaluation of ODs is increasing for both the FDA and the EMA, more so for the former than for the latter. Harmonized methodological standards and transparent reporting frameworks are urgently needed to generate quality evidence that benefits stakeholders.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102586"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145658448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modulating neuroimmune function: The key in taVNS therapy for neurological and psychiatric disorders 调节神经免疫功能：taVNS治疗神经和精神疾病的关键。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-12-13 DOI: 10.1016/j.coph.2025.102601

Xinjiang Zhang , Qi Zou , Jinling Zhang , Peijing Rong , Yu Wang

{"title":"Modulating neuroimmune function: The key in taVNS therapy for neurological and psychiatric disorders","authors":"Xinjiang Zhang , Qi Zou , Jinling Zhang , Peijing Rong , Yu Wang","doi":"10.1016/j.coph.2025.102601","DOIUrl":"10.1016/j.coph.2025.102601","url":null,"abstract":"<div><div>Numerous lines of evidence indicate that the inflammatory state of neural tissue plays a significant role in the pathogenesis of neurological and psychiatric disorders, with neuroinflammation contributing to the dysregulation of cellular immunity and heightened susceptibility to such disorders. Previous research has demonstrated that vagus nerve stimulation (VNS) can attenuate inflammatory responses in both central and peripheral tissues, thereby ameliorating certain neurological disorders and enhancing cognitive function in the brain. Transcutaneous auricular vagal nerve stimulation (taVNS) has been validated in both clinical and preclinical studies as a noninvasive, straightforward, and cost-effective VNS technique. Nevertheless, the mechanisms by which taVNS modulates immunopathological responses within brain tissue remain incompletely understood. Currently, there is a growing body of research investigating the modulation of neuroimmune function as a therapeutic approach for neurological and psychiatric disorders. Several studies have elucidated the molecular mechanisms through which taVNS alleviates depression and cognitive dysfunction by inhibiting central immune inflammation from various perspectives. This review initially delineates the immunoregulatory role of VNS technology and its therapeutic relevance within the central nervous system (CNS). Within the framework of neuroimmune regulation, it offers an exhaustive analysis of pertinent research concerning the application of taVNS in the treatment of neurological and psychiatric disorders, emphasizing the modulation of immunoinflammatory pathways. Furthermore, this review constructs a theoretical framework to elucidate the pathogenic mechanisms of neurological and psychiatric disorders. The investigation into the interaction between VNS and neuroimmune regulatory networks facilitates the identification and development of novel therapeutic targets and pathways.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102601"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management? 从一刀切到基于表型的药物治疗：我们在肥胖管理方面走了多远？

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-19 DOI: 10.1016/j.coph.2025.102589

Theocharis Koufakis , Luca Busetto

{"title":"From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?","authors":"Theocharis Koufakis , Luca Busetto","doi":"10.1016/j.coph.2025.102589","DOIUrl":"10.1016/j.coph.2025.102589","url":null,"abstract":"<div><div>Obesity is a global health crisis, projected to affect over one billion adults by 2030. Lifestyle modification strategies—diet, physical activity, and behavioral therapy—have achieved only modest and often unsustainable outcomes. Pharmacotherapy has therefore emerged as a cornerstone of modern obesity care. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agents such as tirzepatide have demonstrated unprecedented efficacy, with weight reductions approaching surgical outcomes in some populations while improving glycemic and cardiometabolic parameters. These therapeutic advances align with recognition of the pathophysiological heterogeneity of obesity, often conceptualized through four phenotypes: “hungry brain” (impaired satiation), “hungry gut” (impaired satiety), “emotional hunger” (reward-driven eating), and “slow burn” (impaired metabolism). This framework offers a rationale for targeted interventions—GLP-1 receptor agonists for satiety-related phenotypes, naltrexone–bupropion for reward-driven eating, and dual incretin therapies for metabolic inefficiency. Beyond pharmacology, accumulating evidence indicates that surgical outcomes may also differ across patient subgroups, suggesting that phenotype-guided strategies could refine not only medical therapy but also surgical decision-making. However, these phenotypes remain heuristic, with overlapping traits, limited validation, and uncertain predictive value. Future research should refine phenotypic classification, identify reliable biomarkers, and conduct phenotype-stratified clinical trials to confirm matching of pharmacological and surgical interventions.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102589"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies 炎症性肠病的创新管道治疗：抗肿瘤坏死因子样配体1A和双特异性抗体

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-25 DOI: 10.1016/j.coph.2025.102596

Maria Manuela Estevinho , Nurulamin M. Noor

{"title":"Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies","authors":"Maria Manuela Estevinho , Nurulamin M. Noor","doi":"10.1016/j.coph.2025.102596","DOIUrl":"10.1016/j.coph.2025.102596","url":null,"abstract":"<div><div>There has been significant progress made in inflammatory bowel disease (IBD) over the last couple of decades, with a rapidly increasing number of biologic and small molecules treatments. Coupled with a better understanding of when and how to use treatments appropriately, this has resulted in substantial and meaningful improvement in outcomes for many patients. However, an ongoing issue is that around 30–40% of patients either do not respond or lose response to currently available treatments over time, underscoring the need for further novel therapeutic targets and approaches.</div><div>Two particularly exciting novel approaches include a novel class of medications targeting tumor necrosis factor-like ligand 1A (TL1A) and the engagement in two pathogenic pathways simultaneously through the use of bispecific antibodies. The development of both of these potential treatment approaches has been built on decades of translational studies, including initial genetic discovery and immune functional validation. The class of molecules targeting TL1A has shown high potency in the pre-clinical setting and emerging data from early-phase interventional clinical trials have been encouraging. Bispecific antibodies have been used so far mostly in the fields of hematology and oncology, but with promising initial findings in IBD that targeting multiple pathways at once, may offer the prospect of greater remission rates or more durable remission than current strategies seeking to target single immunological pathways in isolation. This narrative review presents the latest evidence evaluating TL1A inhibition and bispecific antibodies, including the development pipeline for these molecules as innovative approaches for the next generation of IBD treatments.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102596"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145738713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acupuncture for depression: Decoding neuroimmune crosstalk and targeting anti-inflammatory mechanisms 针灸治疗抑郁症：解码神经免疫串扰和靶向抗炎机制

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-14 DOI: 10.1016/j.coph.2025.102585

Anni Shi , Wenjing Li , Xiaoling Liu , Jun Lu , Jianyou Guo

{"title":"Acupuncture for depression: Decoding neuroimmune crosstalk and targeting anti-inflammatory mechanisms","authors":"Anni Shi , Wenjing Li , Xiaoling Liu , Jun Lu , Jianyou Guo","doi":"10.1016/j.coph.2025.102585","DOIUrl":"10.1016/j.coph.2025.102585","url":null,"abstract":"<div><div>Depression, a leading global health burden, involves neuroimmune dysregulation and neuroinflammation. As a promising non-pharmacological approach, acupuncture has been supported by numerous studies as an effective intervention for alleviating depression. The antidepressant mechanisms of acupuncture involve a multitarget modulation of neuroimmune crosstalk, such as restoring hypothalamic-pituitary-adrenal (HPA) axis homeostasis, inhibiting microglial and astrocytic activation, regulating autophagy, inhibiting key inflammatory signaling pathways, activating anti-inflammatory pathways via the vagus nerve, and rebalancing gut–brain axis communication by modifying microbiota. Integrating acupuncture with advanced neuromodulation techniques may enhance its effectiveness in treating depression. It needs further study to validate acupuncture as an effective therapeutic strategy in the field of neuroimmunology for depression. This review summarizes evidence elucidating how acupuncture regulates neuroimmune crosstalk in depression. It not only provides a scientific basis for its application but also advances the understanding of the pathophysiology of depression by highlighting the interplay between neuroimmune interaction and inflammatory pathways.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102585"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145658447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining remission targets in inflammatory bowel disease: The rise of ultrasound remission 重新定义炎症性肠病的缓解目标：超声缓解的增加

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-10 DOI: 10.1016/j.coph.2025.102584

Tommaso Innocenti , Armando Curto , Siro Bagnoli , Andrea Galli , Gabriele Dragoni

{"title":"Redefining remission targets in inflammatory bowel disease: The rise of ultrasound remission","authors":"Tommaso Innocenti , Armando Curto , Siro Bagnoli , Andrea Galli , Gabriele Dragoni","doi":"10.1016/j.coph.2025.102584","DOIUrl":"10.1016/j.coph.2025.102584","url":null,"abstract":"<div><div>Mucosal healing has long been the primary therapeutic goal in inflammatory bowel disease (IBD). Although ileocolonoscopy remains the reference standard to explore this target, the invasiveness and limited acceptability of endoscopic procedures have accelerated a move toward noninvasive, cross-sectional assessments that capture transmural disease. In this context, transmural healing has been proposed as an ambitious target that can be evaluated with several tools, including intestinal ultrasound (IUS). IUS has emerged as a radiation-free, bedside tool that enables real-time monitoring of transmural inflammation in both Crohn’s disease) and ulcerative colitis (UC). However, achieving full transmural healing is uncommon with available therapies and currently carries modest prognostic value in UC. To improve clinical decision-making, several standardized IUS activity indices have been developed to provide a more nuanced readout of disease activity and therapeutic response. In this review, we summarize the current evidence on transmural inflammation in IBD and propose to differentiate ‘ultrasound remission,’ as defined by composite IUS scores, from the traditional definition of complete transmural healing.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102584"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145659104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The underlying mechanisms of acupuncture for alleviating pain-induced negative emotions: Synergistic regulation of multiple brain regions 针刺减轻疼痛负性情绪的潜在机制：多脑区的协同调节

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-12-08 DOI: 10.1016/j.coph.2025.102599

Zhen Liu , Chaoyang Zhang , Zelin Chen , Zhifang Xu , Tianyi Zhao

{"title":"The underlying mechanisms of acupuncture for alleviating pain-induced negative emotions: Synergistic regulation of multiple brain regions","authors":"Zhen Liu , Chaoyang Zhang , Zelin Chen , Zhifang Xu , Tianyi Zhao","doi":"10.1016/j.coph.2025.102599","DOIUrl":"10.1016/j.coph.2025.102599","url":null,"abstract":"<div><div>Brain regions associated with pain perception also subsume those involved in emotional regulation, which likely constitutes the physiological basis underlying the comorbidity of pain and negative emotions. Acupuncture has unique advantages compared with drugs. Studies have shown that acupuncture can achieve multi-targeted and bidirectional regulation, simultaneously improving pain and accompanying negative emotional symptoms without causing drug resistance or systemic toxicity. In the hippocampus, acupuncture may contribute to the regulation of painful emotional memory processing by inhibiting ventral hippocampal neuron apoptosis, promoting neurogenesis, and regulating synaptic plasticity. In the anterior cingulate cortex, acupuncture may partially reduce the perception and transmission of pain-related emotions by inhibiting the release of glutamate and the expression of its receptors, enhancing the inhibitory effect of GABAergic receptors. In the medial prefrontal cortex, acupuncture might alleviate inflammatory responses by inhibiting microglial activation and the release of pro-inflammatory cytokines, thereby preserving the integrity of the descending regulatory circuit for painful emotions. This protects the integrity of the descending pain-emotion regulatory circuit. In the amygdala, acupuncture may improve reward deficiency and fear-related abnormal synaptic plasticity by regulating the expression of dopamine receptors, thus avoiding the excessive amplification of pain emotions. This article reviews the mechanisms by which acupuncture improves the induced negative emotions, which is helpful to promote the integration of acupuncture as a complementary approach into the precision medical treatment system for chronic pain-induced anxiety, depression, or comorbidities, and provides a scientific basis for the application of non-pharmacological therapies in neuropsychiatric disorders.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102599"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145840543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI-powered intestinal ultrasound in inflammatory bowel disease: Advancing toward automated disease assessment 炎症性肠病的人工智能肠道超声：朝着疾病自动化评估的方向发展。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-12-08 DOI: 10.1016/j.coph.2025.102598

Irene Zammarchi , Olga Maria Nardone , Rosanna Cannatelli , Subrata Ghosh , Chiara Ricci , Marietta Iacucci

{"title":"AI-powered intestinal ultrasound in inflammatory bowel disease: Advancing toward automated disease assessment","authors":"Irene Zammarchi , Olga Maria Nardone , Rosanna Cannatelli , Subrata Ghosh , Chiara Ricci , Marietta Iacucci","doi":"10.1016/j.coph.2025.102598","DOIUrl":"10.1016/j.coph.2025.102598","url":null,"abstract":"<div><div>The management of inflammatory bowel disease (IBD) relies on accurate disease assessment and close monitoring to guide therapy and evaluate treatment response. While endoscopy remains the gold standard for detecting mucosal inflammation, its invasiveness and inability to fully assess transmural disease or extraintestinal complications limit its use as a stand-alone tool. Cross-sectional imaging modalities, such as CT and MRI, provide accurate evaluations but are hindered by high cost, limited accessibility, and patient burden. Therefore, intestinal ultrasound (IUS) has emerged as a safe, non-invasive, and reproducible modality to evaluate transmural inflammation and complications in real time, making it increasingly relevant for both Crohn's disease and ulcerative colitis. However, challenges such as operator dependence, variability in image acquisition, and lack of standardize protocols have limited its widespread adoption.</div><div>Artificial intelligence (AI) offers transformative potential to overcome these barriers by automating image analysis, standardising interpretation, and reducing interobserver variability. Early applications have shown promise in bowel wall segmentation and thickness assessment, with future opportunities to further integrate imaging features with biomarkers, clinical data, and multi-omics for precision medicine.</div><div>This review aims to explore the current and future roles of IUS, summarizing the potential of AI in IUS to improve diagnostic accuracy, enhance disease monitoring, and enable personalized patient management. We will discuss the strengths and limitations of existing approaches, highlight barriers to clinical implementation, and outline perspectives on how AI-enhanced IUS may transform both research and routine care in IBD.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102598"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145866395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipidomics-driven insights into acupuncture mechanisms: From dynamic signaling networks to multi-dimensional regulations 脂质组学对针灸机制的洞察：从动态信号网络到多维调节。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-12-11 DOI: 10.1016/j.coph.2025.102600

Xi Ruan , Junqi Zhou , Lizhexiong Song , Changfeng Hu , Xuanming Hu

{"title":"Lipidomics-driven insights into acupuncture mechanisms: From dynamic signaling networks to multi-dimensional regulations","authors":"Xi Ruan , Junqi Zhou , Lizhexiong Song , Changfeng Hu , Xuanming Hu","doi":"10.1016/j.coph.2025.102600","DOIUrl":"10.1016/j.coph.2025.102600","url":null,"abstract":"<div><div>This review summarizes lipidomics as a key approach to dissect the multi-dimensional regulatory mechanisms of acupuncture, and reveals the role of lipid networks serve as critical ‘molecular transducers’ in the conversion of mechanical stimulation to biochemical signals. It systematically illustrates how lipid molecules mediate acupuncture's integrative regulation of the ‘metabolic-immune-neurological’ system through five-dimensional networks, including metabolic reprogramming, transmembrane signaling transduction, immune microenvironment regulation, cell death regulation, and neuroepigenetic communication. By integrating advanced lipidomics technologies (including high-resolution mass spectrometry, spatial analysis, and single-cell platforms) with multi-omics approaches and artificial intelligence (AI)-driven predictive modeling, a precise three-dimensional map of ‘acupuncture point-lipid targets–effector pathways’ is constructed. Overcoming the technical challenges in lipid isomer detection and in vivo lipid imaging is crucial. This advancement will facilitate a paradigm shift in medicine by enabling precise, personalized acupuncture and moxibustion treatments guided by lipid biomarkers. It also highlights the scientific value of integrating systems biology with traditional medicine.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102600"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145901481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0